Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as a...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Long-term Depression01:03

Long-term Depression

Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over time, all...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The effect of empagliflozin on inflammation in patients with overweight or obesity and risk of heart failure: a substudy from the Empire Prevent Metabolic trial.

Cardiovascular diabetology·2026
Same author

The Effect of Empagliflozin on Left Ventricular Mass and Volumes in Older Adult Individuals With Overweight and High Risk of Heart Failure: The Empire Prevent Cardiac Trial.

Journal of cardiac failure·2026
Same author

Optimizing the protocol for modified natural cycle frozen embryo transfer (mNC-FET): a multicentre, single-blinded randomized controlled trial.

Human reproduction open·2026
Same author

Effect of digital intervention in the self-management of depressive symptoms: the MENTINA trial - a study protocol for a randomised controlled parallel-group trial.

BMJ open·2026
Same author

Antithrombotic agents in the treatment of severe mental illness: A systematic review and meta-analysis of randomized controlled trials.

Neuroscience and biobehavioral reviews·2026
Same author

Patient experiences with brain <sup>1</sup>H proton and <sup>7</sup>Lithium magnetic resonance imaging before and during lithium treatment for bipolar affective disorder: a qualitative analysis.

International journal of bipolar disorders·2026
Same journal

Biofluid Biomarkers of Cognitive Functioning in Bipolar Disorder: A Systematic Review by the Targeting Cognition and Older-Age Bipolar Disorder ISBD Task Forces.

Bipolar disorders·2026
Same journal

Enhancing Affective Cognitive Control in Bipolar Disorder Using Transcranial Alternating Current Stimulation: A Double-Blind, Randomized, Sham-Controlled Clinical Trial and Proof of Concept Study.

Bipolar disorders·2026
Same journal

Psychotropic Prescribing Patterns Among Bipolar-I Patients Prior to Established Bipolar-I Disorder Diagnosis.

Bipolar disorders·2026
Same journal

Speech and Language Markers of Bipolar Disorder: Challenges and Opportunities.

Bipolar disorders·2026
Same journal

Can We Improve the Prediction of Early Onset Mania and Hypomania in the Community?

Bipolar disorders·2026
Same journal

How Do Parents With Bipolar Disorder Perceive the Risk to the Next Generation? Results From a Qualitative Study.

Bipolar disorders·2026
See all related articles

Related Experiment Video

Updated: Jun 16, 2026

Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells
12:55

Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells

Published on: October 10, 2017

Does lithium protect against dementia?

Lars Vedel Kessing1, Julie Lyng Forman, Per Kragh Andersen

  • 1Department of Psychiatry, University Hospital of Copenhagen. Copenhagen, Denmark. lars.kessing@rh.dk

Bipolar Disorders
|February 13, 2010
PubMed
Summary
This summary is machine-generated.

Lithium treatment in patients with bipolar disorder may reduce dementia risk. Continued lithium use showed a decreased dementia rate, unlike other psychiatric medications.

Related Experiment Videos

Last Updated: Jun 16, 2026

Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells
12:55

Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells

Published on: October 10, 2017

Area of Science:

  • Neuroscience
  • Psychiatry
  • Gerontology

Background:

  • Bipolar disorder and mania are significant psychiatric conditions.
  • Dementia poses a growing public health challenge.
  • The potential neuroprotective effects of psychiatric medications are of interest.

Purpose of the Study:

  • To determine if lithium treatment in patients with mania or bipolar disorder is linked to a lower incidence of subsequent dementia.

Main Methods:

  • Utilized Danish register data linking lithium prescriptions to dementia diagnoses in patients with mania or bipolar disorder (1995-2005).
  • Included 4,856 patients with manic/mixed episodes or bipolar disorder at their first psychiatric contact.
  • Analyzed dementia rates based on exposure to lithium, anticonvulsants, antidepressants, and antipsychotics.

Main Results:

  • A total of 216 patients were diagnosed with dementia during the follow-up period.
  • The rate of dementia decreased after the second prescription of lithium compared to the first.
  • No significant decrease in dementia rates was observed with continued use of anticonvulsants, antidepressants, or antipsychotics.

Conclusions:

  • Continued lithium treatment appears associated with a reduced dementia rate in bipolar disorder patients.
  • This contrasts with continued treatment using anticonvulsants, antidepressants, or antipsychotics.
  • The non-randomized nature of the data necessitates caution regarding potential methodological biases.